Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Global biosimilar companies face regulatory challenges in China

This article was originally published in SRA

Executive Summary

Chinese regulatory requirements are making it difficult for biosimilar companies to incorporate China into global development programs, and, according to senior Pfizer representative, despite efforts by the country to clarify its biosimilar regulatory process through recent guidance, developing a biosimilar for the Chinese market continues to pose challenges.